The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TNXP | +4.89% | -100% | -86.54% | -100% |
| S&P | +14.5% | +93.32% | +14.09% | +398% |
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.
A spot of potentially good news can't stop the investor exodus from the biotech stock.
The sell-off that began on Monday continues.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $2.00M | -9.5% |
| Gross Profit | -$1.76M | 25.7% |
| Gross Margin | -87.94% | 19.1% |
| Market Cap | $264.71M | 16375.5% |
| Market Cap / Employee | $3.27M | 0.0% |
| Employees | 81 | -21.4% |
| Net Income | -$28.27M | 64.1% |
| EBITDA | -$27.81M | -62.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $125.33M | 2915.7% |
| Accounts Receivable | $4.22M | 26.3% |
| Inventory | 6 | -36.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.30M | -95.2% |
| Short Term Debt | $0.20M | -93.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -63.20% | 66.4% |
| Return On Invested Capital | -69.15% | 42.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$16.76M | -77.1% |
| Operating Free Cash Flow | -$16.21M | -71.2% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.31 | 0.01 | 0.56 | 1.37 | 9106.71% |
| Price to Sales | 0.82 | 0.07 | 10.55 | 26.82 | 11626.41% |
| Price to Tangible Book Value | 3.48 | 69.28 | 0.56 | 1.37 | -97.39% |
| Enterprise Value to EBITDA | 0.69 | 4.09 | 1.62 | -4.99 | 976.64% |
| Return on Equity | -138.7% | -106.1% | -91.4% | -77.5% | -52.52% |
| Total Debt | $8.69M | $8.12M | $0.56M | $0.49M | -94.69% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
